State drug price transparency requirements continue to expand, with over 20 states mandating WAC reporting at launch, during price increases, and on recurring schedules. As legislation evolves and oversight mechanisms like Prescription Drug Affordability Review Boards (PDABs) gain traction, manufacturers face growing pressure to stay compliant while managing increasing data complexity. Join us for a focused discussion on the latest regulatory updates and practical strategies to streamline reporting, enhance auditability, and reduce manual effort.

Agenda Highlights:

• Key legislative updates impacting reporting requirements
• The evolving PDAB landscape
• Critical data considerations for compliance
• How automation can improve efficiency and control

Sponsored by:

Speakers:

Ritu Pandey
Principal
Marbls

Stephanie Kupski
Sr. Director, Pricing Operations
CSL Behring